Article Text

Download PDFPDF

EP317/#772  A targeted homogenous recombination gene panel for epithelial ovarian carcinomas with different histological subtypes and clinical outcomes
  1. Yenhan Wang1,
  2. Po-Han Lin2,
  3. Kuan-Ting Kuo3,
  4. Yi-Jou Tai4,
  5. Heng-Cheng Hsu4,
  6. Chi-An Chen4,
  7. Wen-Fang Cheng4 and
  8. Ying-Cheng Chiang4
  1. 1National Taiwan University Hospital Hsin-Chu Branch, Department of Obstetrics and Gynecology, Hsin-Chu, Taiwan
  2. 2National Taiwan University Hospital, Department of Medical Genetics, Taipei, Taiwan
  3. 3National Taiwan University Hospital, Department of Pathology, College of Medicine, Taipei, Taiwan
  4. 4National Taiwan University Hospital, Department of Obstetrics and Gynecology, College of Medicine, Taipei, Taiwan


Introduction In recent years, promising survival benefits from maintenance therapy with poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) has changed the management of epithelial ovarian cancer (EOC) in newly diagnosed and recurrent disease. Identification of BRCA and/or homologous recombination (HR) gene mutation is critical for selecting patients for PARPi treatment and as a prognostic and predictive biomarker in high-grade serous carcinoma (HGSOC), yet its role in other histology remains controversial. Our study aims to retrospectively analyze the correlation of BRCA/HR gene mutation with the clinical outcomes of EOC patients.

Methods 318 women diagnosed with EOC who had received debulking surgery and platinum-based adjuvant chemotherapy at NTUH were retrospectively reviewed. The tumor tissue was sent for genetic analysis for somatic mutation of genes in HR gene panel, including BRCA 1/2. Clinical data were obtained from medical records.

Results 25.4% of patients with HGSOC (n = 177) had BRCA/HR mutation and showed better sensitivity to platinum-based chemotherapy (83.9% vs. 69.5%, P=0.029) and longer progression-free survival (PFS) (P=0.004 and <0.001, respectively). However, only 7.8% of patients with non-serous histology had BRCA/HR mutation and showed no correlation with platinum sensitivity, PFS, or overall survival. Through the multivariate analysis, we confirmed the protective effect of BRCA/HR mutation with disease recurrence and death in patients with HGSOC yet no effect was found on non-serous histologic type.

Conclusion/Implications BRCA/HR mutation is a prognostic biomarker in HGSOC yet not in non-serous patients. Further study is needed to follow up on the clinical response to PARPi in these patients and find out other proper prognostic biomarkers.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.